Quisinostat (JNJ-26481585) 2HCl

For research use only. Not for use in humans.

目录号:S1096

Quisinostat (JNJ-26481585) 2HCl Chemical Structure

CAS No. 875320-31-3

Quisinostat (JNJ-26481585) 2HCl是一种新型的,第二代HDAC抑制剂,对HDAC1最有效,无细胞试验中IC50为0.11 nM,作用于HDACs 2,4,10,和11适度有效;比作用于HDACs 3,5,8,和9选择性强30倍,对HDACs 6和7作用效果最弱。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2691.01 现货
RMB 1726.45 现货
RMB 7921.36 现货
RMB 20229.3 现货
有超大折扣
今日订购,明日送达 全国免运费 分装免费
全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Quisinostat (JNJ-26481585) 2HCl发表文献47篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Quisinostat (JNJ-26481585) 2HCl是一种新型的,第二代HDAC抑制剂,对HDAC1最有效,无细胞试验中IC50为0.11 nM,作用于HDACs 2,4,10,和11适度有效;比作用于HDACs 3,5,8,和9选择性强30倍,对HDACs 6和7作用效果最弱。Phase 2。
特性 JNJ-26481585是口服生物有效性的,二代氧肟酸基的HDAC抑制剂。
靶点
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
HDAC11 [1]
(Cell-free assay)
HDAC10 [1]
(Cell-free assay)
HDAC4 [1]
(Cell-free assay)
0.11 nM 0.33 nM 0.37 nM 0.46 nM 0.64 nM
体外研究

体外, JNJ-26481585有效抑制一组重组HDAC酶,最有效抑制HDAC1,IC50为 0.11 nM,另外抑制其他家族成员如HDAC2, 4, 10和 11时效果稍微低点,IC50分别为0.33 nM, 0.64 nM, 0.46 nM 和0.37 nM。[1] JNJ-26481585 作用于实体瘤和血癌细胞系,如肺癌,乳腺癌,结肠癌,前列腺癌,脑癌,和卵巢癌细胞系,IC50 为3.1 到 246 nM,具有广谱抗增殖活性,作用于多种人类癌细胞系时,JNJ-26481585效果比 Vorinostat, R306465, Panobinostat, CRA-24781, 和 Mocetinostat 好。[1] 最新研究显示JNJ-26481585 在低纳摩尔浓度时通过耗尽Mcl-1及诱导Hsp72产生而促进骨髓癌细胞死亡。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 cells NYXCRYVHS2WubDD2bYFjcWyrdImgZZN{[Xl? NYO1dmRTOjRuIES4MEBweiB5MjDo MoWweIhmKEmFNUCgeoFtfWW|IH;mJINmdGy|IH\vdkA1QCCjbnSgO|IhcCCxZjDxeYl{cW6xc4TheEB1emWjdH3lcpQhf2W{ZTC4Nk41KGGwZDC0Nk4xKG6PLDDy[ZNx\WO2aY\lcJkv NUXM[GVWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0NlM1PTRpPkK3OFI{PDV2PD;hQi=>
RH30 cells MXTGeY5kfGmxbjDhd5NigQ>? M{P1XVE2KG6P M2TsRVI1KGhiYX7kJFMxKGh? MULHV2s3QTBiYX7kJGpPUi1{NkS4NVU5PSClb3;w[ZJifGWmIITvJIlv\HWlZTDjcIVifmGpZTDv[kB1cGViaX7peIlifG:{IHPhd5Bie2VvOTDpcpRwKGm2czDhZ5RqfmVicEO1JIFv\CCyM{eg[pJi\22nboTzJIFv\CCxZjD0bIUh\W[oZXP0c5Ih[2G|cHHz[U0{KGmwdH:gbZR{KGGldHn2[UBxOTJiYX7kJJAyPyCocnHncYVvfHN? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZzN{S0NUc,Ojh4MUe0OFE9N2F-
RD cells NGr3b3FHfW6ldHnvckBie3OjeR?= NHTXUmQyPSCwTR?= MkTQNlQhcCCjbnSgN|AhcA>? NESzT2tIW0t4OUCgZY5lKEqQSj2yOlQ5OTV6NTDjc49x\XKjdHXkJJRwKGmwZIXj[UBkdGWjdnHn[UBw\iC2aHWgbY5qfGmjdH;yJINie3Cjc3WtPUBqdnSxIHn0d{Bi[3SrdnWgdFM2KGGwZDDwN|ch\nKjZ33lcpR{KGGwZDDv[kB1cGViZX\m[YN1d3JiY3HzdIF{\S1|IHnueI8hcXS|IHHjeIl3\SCyMUKgZY5lKHBzNzDmdoFodWWwdIO= NWHV[FJnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2NVc1PDFpPkK4OlE4PDRzPD;hQi=>
HepG2 NELaW4pE\WyuII\pZYJqdGm2eTDhd5NigQ>? M2rUfVUtKDFyLDCyNEwhPDBuIEiwMEAyPjBiYX7kJFMzOCCwTR?= MlXXNlQtKDR6LDC3NkBp M1LSZnRp\SCLQ{WwJJZidHWnczDv[kBk\WyuczDmc5IheXWrc3nuc5N1[XRidILlZZRu\W62IHH0JFQ5KGGwZDC3NkBpKHencnWgPFEvOiCjbnSgN|AvQCCwTTygdoV{eGWldHn2[Yx6Ng>? NXP3UplMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OFkxQDBpPkK4PFQ6ODhyPD;hQi=>
HuT78 MlLrSpVv[3Srb36gZZN{[Xl? NWG3bINyOTBibl2= MXzpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKGGlZYT5cIF1\WRibInzbY5mKEtzMDDv[kBpcXO2b37lJGg{ NX75c5hmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNVI1OThpPkOwNFEzPDF6PD;hQi=>
Sf9 M{eySGZ2dmO2aX;uJIF{e2G7 MnvDTY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDy[YNwdWKrbnHueEBpfW2jbjDISGFEOSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHPlcIx{KHW|aX7nJHJJU0tvQXOgZZMhe3Wkc4TyZZRmKGK7IH\seY9z\XOlZX7j[UBidmGueYPpd{whUUN3MDC9JFAvODByMUGg{txONg>? MmrnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4ME[1OFYoRjJ5NkC2OVQ3RC:jPh?=
Sf9 MlqzSpVv[3Srb36gZZN{[Xl? NVLyWnZOUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBz\WOxbXLpcoFvfCCqdX3hckBJTEGFMjDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[5JINmdGy|IIXzbY5oKFKKS1utRYMh[XNic4Xid5Rz[XSnIHL5JIZtfW:{ZYPj[Y5k\SCjbnHsfZNqeyxiSVO1NEA:KDBwMECwN|Mh|ryPLh?= M{jBd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NkC2OVQ3Lz5{N{[wOlU1PjxxYU6=
Sf9 NGfvUGRHfW6ldHnvckBie3OjeR?= NIH6e49KdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJJJm[2:vYnnuZY51KGi3bXHuJGhFSUN|L17DU3IzKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliY3XscJMhfXOrbnegVmhMUy2DYzDhd{B{fWK|dILheIUh[nliZnz1c5Jme2OnbnPlJIFv[Wy7c3nzMEBKSzVyIE2gNE4xODR6NjFOwG0v NX;PTWFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2NFY2PDZpPkK3OlA3PTR4PD;hQi=>
HUT78 M1vOUmZ2dmO2aX;uJIF{e2G7 M2i1bVE5KGi{cx?= MYHQdo8u[XCxcITveIlkKGGldHn2bZR6KGmwIHj1cYFvKEiXVEe4JINmdGy|IHHmeIVzKDF6IHjyd{BjgSClYYPwZZNmNUeubzCzM|ch[XO|YYmsJGVEPTBiPTCwMlAxPjVizszNMi=> NVe4SWlxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxNlIzOjdpPkOwNVIzOjJ5PD;hQi=>
BL21 (DE3) MoXYSpVv[3Srb36gZZN{[Xl? M1XRdmJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6gTIl{NXSqaX;y[YRwgGmwLYTh[4dm\CCKRFHDPEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJEhFTTNrIHPlcIx{KGK7IFnUR{Bu\XSqb3SsJGtlKD1iMD6wNlI4KM7:TT6= NICybWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEO0O|E1QCd-M{CzOFcyPDh:L3G+
BL21 (DE3) MXPGeY5kfGmxbjDhd5NigQ>? MlHRRolv\GmwZzDh[oZqdmm2eTD0c{BU[2irc4Tvd49u[SCvYX7zc45qKEircz30ZYdo\WRiSFTBR|gh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUApTEV|KTDj[YxteyCkeTDJWGMhdWW2aH;kMEBM\CB;IECuNFI5PCEQvF2u NH;CS2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEO0O|E1QCd-M{CzOFcyPDh:L3G+
BL21 (DE3) NXHJcohITnWwY4Tpc44h[XO|YYm= M3fiXWlvcGmkaYTpc44hd2ZiaIXtZY4hUGm|LYTobY9z\WSxeHnuMZRi\2enZDDISGFEQCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKCiGRUOpJINmdGy|IIXzbY5oKE[udX;yJIRmKEy7czCoVkkuUESDQ{igZZMhe3Wkc4TyZZRmKGK7IH\seY9zd22ndILpZ{Bu\XSqb3SsJGlEPTBiPTCwMlA3PDRizszNMi=> M1S2XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{S3NVQ5Lz5|MEO0O|E1QDxxYU6=
Sf9 MV\GeY5kfGmxbjDhd5NigQ>? NEnpdGlKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJJJm[2:vYnnuZY51KGi3bXHuJGhFSUN4IHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkmgZ4VtdHNidYPpcochWkiNSz3BZ{BieyC|dXLzeJJifGViYomg[ox2d3Knc3PlcoNmKGGwYXz5d4l{NCCLQ{WwJF0hOC5yN{[4JO69VS5? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzZyNkW0Okc,Ojd4ME[1OFY9N2F-
BL21 (DE3) NGT4PVdHfW6ldHnvckBie3OjeR?= MoKyTY5pcWKrdHnvckBw\iCqdX3hckBJcXNvdHjpc5Jm\G:6aX6teIFo\2WmIFjERWM5KG2ONjDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSBqRFWzLUBk\WyuczD1d4lv\yCIbIXvdkBl\SCOeYOgLHIqNUiGQVO4JIF{KHO3YoP0doF1\SCkeTDmcJVwem:vZYTybYMhdWW2aH;kMEBKSzVyIE2gNE4xQTNizszNMi=> NWrvc3lMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOFcyPDhpPkOwN|Q4OTR6PD;hQi=>
BL21 (DE3) Mn71SpVv[3Srb36gZZN{[Xl? NI\XcFJKdmirYnn0bY9vKG:oIHj1cYFvKEircz30bIlwemWmb4jpck11[WepZXSgTGRCSzhibVyxM41NPiCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUApTEV|KTDj[YxteyC3c3nu[{BHdHWxcjDk[UBNgXNiKGKpMWhFSUN6IHHzJJN2[nO2cnH0[UBjgSCobIXvdo9u\XS{aXOgcYV1cG:mLDDJR|UxKD1iMD6wPVQh|ryPLh?= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2N{G0PEc,OzB|NEexOFg9N2F-
BL21 (DE3) NHraUFZHfW6ldHnvckBie3OjeR?= MofYTY5pcWKrdHnvckBw\iCqdX3hckBJcXNvdHjpc5Jm\G:6aX6teIFo\2WmIFjERWM5KG2ONj;MNVc6USCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUApTEV|KTDj[YxteyC3c3nu[{BHdHWxcjDk[UBNgXNiKGKpMWhFSUN6IHHzJJN2[nO2cnH0[UBjgSCobIXvdo9u\XS{aXOgcYV1cG:mLDDJR|UxKD1iMD6xOlkh|ryPLh?= NGT4Umk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEO0O|E1QCd-M{CzOFcyPDh:L3G+
BL21 (DE3) NVTVeIppTnWwY4Tpc44h[XO|YYm= NV7kSFF1UW6qaXLpeIlwdiCxZjDoeY1idiCKaYOteIhqd3KnZH;4bY4ufGGpZ3XkJGhFSUN6IH3MNU9uVDZxTEG3PWkhdXW2YX70JIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKEKOMkGgLGRGOyliY3XscJMhfXOrbnegSox2d3JiZHWgUJl{KCiUKT3ISGFEQCCjczDzeYJ{fHKjdHWgZpkh\my3b4LvcYV1emmlIH3leIhw\CxiSVO1NEA:KDBwMkG3JO69VS5? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2N{G0PEc,OzB|NEexOFg9N2F-
BL21 (DE3) MVzGeY5kfGmxbjDhd5NigQ>? M2fDbmlvcGmkaYTpc44hd2ZiU3PobZN1d3OxbXGgcYFve2:waTDIbZMufGGpZ3XkJGhFSUN6IHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFiKFTFN{kh[2WubIOgeZNqdmdiRnz1c5Ih\GViTInzJEhTMS2KRFHDPEBieyC|dXLzeJJifGViYomg[ox2d3KxbXX0dolkKG2ndHjv[EwhUUN3MDC9JFAvOzB|NDFOwG0v MmDVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|NEexOFgoRjNyM{S3NVQ5RC:jPh?=
TC32 NHPYcXdyUFSVIHHzd4F6 MlrSdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN? NXflNlBPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS NWL1UldseUiWUzDhd5NigQ>? MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy| MkftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 M2Ow[JFJXFNiYYPzZZk> MX\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? M4\EZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY MY\xTHRUKGG|c3H5 MWnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? NF;kRZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 NH;jNXNyUFSVIHHzd4F6 MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 NWm0VHBreUiWUzDhd5NigQ>? MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD NUPmVVJPeUiWUzDhd5NigQ>? NFizNY5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH M4rxbZFJXFNiYYPzZZk> MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-12 MWrxTHRUKGG|c3H5 MnXsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy| M{DsZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) M3jPVJFJXFNiYYPzZZk> NYrOS2FweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz NXPnNnFvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 M1nmb5FJXFNiYYPzZZk> NFXCbnJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 NGrlVVdyUFSVIHHzd4F6 Mn71dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= NXzySllURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 NXjZ[oFGeUiWUzDhd5NigQ>? M{LiVJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTF{IHPlcIx{ M3vhNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY NXHsdpBMeUiWUzDhd5NigQ>? NWjqZpQ1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? NFGzOmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
fibroblast cells MlrPdWhVWyCjc4PhfS=> MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5Ih[2:wdILvcEBJcCC5aXzkJJR6eGViZnnido9jdGG|dDDj[Yxtew>? MnjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH NVTtTHdkeUiWUzDhd5NigQ>? NWHlN|V3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 MUDxTHRUKGG|c3H5 M3;Tc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy| MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 NHjYNGRyUFSVIHHzd4F6 NIH5VVRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd|IHPlcIx{MQ>? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 MVTxTHRUKGG|c3H5 NIH4T21yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?= M3LxSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) MYrxTHRUKGG|c3H5 NGLQbVJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>? NW\tSFhtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
fibroblast cells NXvuXnd3eUiWUzDhd5NigQ>? M1LabpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJINwdnS{b3ygTIghf2muZDD0fZBmKG[rYoLvZoxie3RiY3XscJM> Mn3xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh30 M2jybpFJXFNiYYPzZZk> NVGxO5M2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh|MDDj[Yxtew>? NEfzS2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
U-2 OS NWTqOmhPeUiWUzDhd5NigQ>? MYPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDVMVIhV1NiY3XscJM> M1v2[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 MXnxTHRUKGG|c3H5 NUK0fWdieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| MnPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH NIH2TXdyUFSVIHHzd4F6 MXLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN? M2fK[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 M4ftbZFJXFNiYYPzZZk> MnXldWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=> NXr1XmZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD Mm\odWhVWyCjc4PhfS=> MmjjdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVmQh[2WubIO= NUHq[JdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Daoy MUDxTHRUKGG|c3H5 NUTI[G0xeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCGYX;5JINmdGy| MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 M{LHWpFJXFNiYYPzZZk> NX\MNWNjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCWQ{OyJINmdGy| NWfseG9vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) MWrxTHRUKGG|c3H5 NUnQOlJmeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= M4j3[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 MUfxTHRUKGG|c3H5 Mo[0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= M2TZT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC NIDSNnByUFSVIHHzd4F6 NV\F[ndSeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> NH\jWZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 Moq1dWhVWyCjc4PhfS=> MXnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= M1nkcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 MnzodWhVWyCjc4PhfS=> MXLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? M{LYZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 NV;pNoJ1eUiWUzDhd5NigQ>? NUG4[Y9GeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO= NFnUemE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 NWLOfVVseUiWUzDhd5NigQ>? MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORlE3PDNiY3XscJM> MmrNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 M2r0c5FJXFNiYYPzZZk> Ml3DdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2ouT0KPMjDj[Yxtew>? NXjXfHhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18 NYf4WXJieUiWUzDhd5NigQ>? MomydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=> NVXxeGg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 MXnxTHRUKGG|c3H5 NF;rOHFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBU[W:|LUKgZ4VtdHN? MnrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 M{\kUZFJXFNiYYPzZZk> MWfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHNLNUeETUKgZ4VtdHN? MoXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD M2f5OJFJXFNiYYPzZZk> MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHJFKGOnbHzz MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
HDAC1 / HDAC2 / HDAC4; 

PubMed: 30443188     


The effects of quisinostat on the expressions of HDACs in HCC cells. The expression levels of HDAC1, HDAC2 and HDAC4 were suppressed in both HCCLM3 and SMMC-7721 cell lines. Images were photographed with confocal microscope under ×200 magnification. Scale bar, 100 μm. Data were shown as mean ± SD. n = 3; * P < 0.05, ** P < 0.01 and *** P < 0.001 compared with DMSO group.

p21 / CDK2 / CDK4 / CDK6 / Cyclin D1 / Cyclin E1 / Cyclin A2; 

PubMed: 30443188     


Western blot analysis of p21, cdk2, cdk4, cdk6, cyclinD1, cyclinE1 and cyclinA2 proteins after quisinostat treatment. 

Caspase-3/ Cleaved caspase-3 / caspase-9 / Cleaved caspase-9 / PARP / Cleaved PARP / Bcl-xl / Bcl2 / Bax / Survivin; 

PubMed: 30443188     


Western blot analysis of Caspase-3, cleaved-Caspase-3, Caspase-9, cleaved-Caspase-9, PARP, cleaved-PARP, Bcl-xl, Bcl2, Bax and survivin protein were carried out after quisinostat treatment. 

PI3K-p110 / PI3K-p85 / p-AKT / JNK / p-JNK / p-c-Jun ; 

PubMed: 30443188     


HCCLM3 and SMMC-7721 cells were treated with quisinostat (12.5, 25.0 and 50.0nM) for 48 h. Western blot analysis was used to evaluate expressions of PI3K-p110, PI3K-p85, phosphorylation of AKT473, JNK, phosphorylation of JNK and c-Jun.

30443188
Growth inhibition assay
Cell viability; 

PubMed: 30443188     


Quisinostat inhibited cell proliferation in HCCLM3, Sk-hep-1, Hep-3B, Huh7 and SMMC-7721 cells as a concentration-dependent manner verified by CCK8 assay. 

30443188
体内研究 JNJ-26481585按最大耐受剂量(10 mg/kg腹腔注射及40 mg/kg口服处理)作用于对HDAC1敏感的A2780卵巢癌模型3天,导致产生HDAC1-调节的荧光, 可测的抑制肿瘤生长效果。而且, 与5-fluorouracil/Leucovorin相比,JNJ-26481585更有效抑制C170HM2大肠癌肝转移。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

HDAC 活性实验 :

使用杆状病毒感染的Sf9细胞表达全长HDAC蛋白。此外, HDAC3共表达作为与人类NCOR2作用的复合体。为了测定含HDAC1细胞复合体活性, 免疫沉淀反应的HDAC1复合体和组蛋白H4肽段[生物素-(6-氨基)Gly-Ala-(乙酰基[3H])Lys-Arg-His-Arg-Lys-Val-NH2]的[3H]乙酰基标记的片段在50μL酶实验buffer(25mM HEPES (pH 7.4),1 M 蔗糖, 0.1 mg/mL BSA 和0.01% (v/v) Triton X-100)中温育。在37oC下温育45分钟,或者在室温下温育30分钟。加入底物之前,加入浓度不断增加的HDAC抑制剂,然后在室温下预温育10分钟。温育后,加入35μL 终止 buffer (1 M HCl 和0.4 M 乙酸)终止反应。用800μL乙酸乙酯提取释放 [3H]乙酸,然后通过闪烁计数器量化。通过Western blot 分析,测定等量的进行免疫沉淀反应的HDAC1。
细胞实验:[1]
- 合并
  • Cell lines: NCL-H2106, Colo699和 LNCAP
  • Concentrations: 0到300 nM
  • Incubation Time: 24 小时
  • Method: 使用MTT测定HDAC抑制剂抑制细胞增殖的效果。使用Alamar Blue法测定非小细胞肺癌(NSCLC)细胞系的增殖。为了测定 血癌细胞系的增殖,细胞温育72小时,通过 MTS实验测评毒性。进行三次平行实验,测定 IC50。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 在腹股沟区皮下注射HCT116人类结肠癌细胞的雄性NMRI nu/nu无胸腺鼠, 腹腔注射溶于1 mL 0.9% NaCl(pH 7.3)的C170HM2细胞悬浮液的雄性MFI裸鼠
  • Dosages: ≤10 mg/kg
  • Administration: 口服处理或腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 79 mg/mL (169.02 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 467.39
化学式

C21H28Cl2N6O2

CAS号 875320-31-3
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02948075 Completed Drug: Quisinostat|Drug: Paclitaxel|Drug: Carboplatin Ovarian Cancer NewVac LLC|Janssen Pharmaceutica N.V. Belgium September 2015 Phase 2
NCT01464112 Completed Drug: JNJ-2641585 / VELCADE / Dexamethasone Multiple Myeloma Janssen Research & Development LLC September 16 2011 Phase 1
NCT00676728 Terminated Drug: JNJ-26481585 Advanced or Refractory Leukemia|Myelodysplastic Syndromes Johnson & Johnson Pharmaceutical Research & Development L.L.C. December 2008 Phase 1
NCT00677105 Completed Drug: JNJ-26481585 Lymphoma|Neoplasms Johnson & Johnson Pharmaceutical Research & Development L.L.C.|Janssen Pharmaceutica N.V. Belgium August 2007 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I was thinking of resuspending the powder in 10% hydroxy-propyl-β-cyclodextrin, 25mg/ml mannitol, in sterile water (final pH 8.7). Is this a good vehicle to use? What is the solubility of this chemical in such a vehicle?

  • 回答:

    This vehicle can be used for in vivo studies. The following papers also used this vehicle: 1. http://www.nature.com/leu/journal/v23/n10/full/leu2009121a.html; 2. http://cancerres.aacrjournals.org/content/69/13/5307.long (The solvent contains 10% hydroxypropyl-β-cyclodextrin, 0.8% HCl (0.1 N), 0.9 % NaOH (0.1 N), 3.4% mannitol and pyrogen-free water). The solubility is 2mg/ml.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Quisinostat (JNJ-26481585) 2HCl | Quisinostat (JNJ-26481585) 2HCl供应商 | 采购Quisinostat (JNJ-26481585) 2HCl | Quisinostat (JNJ-26481585) 2HCl价格 | Quisinostat (JNJ-26481585) 2HCl生产 | 订购Quisinostat (JNJ-26481585) 2HCl | Quisinostat (JNJ-26481585) 2HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID